Nabriva Therapeutics Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

H. Hogan

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

H. Hogan (60 yo)

less than a year

Permanencia

Mr. H. Michael Hogan III is Chief Executive Officer of Nabriva Therapeutics plc from July 6, 2023. He serves as Director of Metacrine, Inc. since March 23, 2023. He is Director of Otonomy, Inc. from Februa...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Colin Broom	Director	6.2yrs	US$40.00k	0.042% $ 663.6
H. Hogan	Chief Executive Officer	less than a year	sin datos	sin datos
David Maggio	Chief Financial Officer	less than a year	sin datos	sin datos
J. Naftzger	General Counsel & Secretary	2.2yrs	sin datos	sin datos

1.3yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NTY no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Colin Broom	Director	6.4yrs	US$40.00k	0.042% $ 663.6
Daniel Burgess	Independent Chairman of the Board	6.4yrs	US$90.00k	0.013% $ 201.1
Mark H. Corrigan	Independent Director	2.4yrs	US$50.00k	0.0089% $ 139.5
Stephen Webster	Independent Director	6.4yrs	US$65.00k	0.014% $ 221.0
Steven Gelone	Director	2.7yrs	US$579.23k	0.041% $ 641.4
Charles Rowland	Independent Director	6.4yrs	US$55.00k	0.019% $ 295.7
Theodore Schroeder	Director	5.3yrs	US$753.56k	0.26% $ 4.1k
Lisa Dalton	Independent Director	2.4yrs	US$47.50k	0.011% $ 176.5
Carrie Bourdow	Independent Director	6.4yrs	US$52.50k	0.012% $ 192.0

6.4yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de NTY se considera experimentada (6.4 años de antigüedad promedio).

Nabriva Therapeutics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

CEO & Director recently bought €51k worth of stock

Less than half of directors are independent

Nabriva Therapeutics Appoints Steven Gelone to Its Board of Directors

Recent updates

Nabriva Therapeutics plc Files Form 15

Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics

Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index

Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc announced delayed 10-Q filing

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Nabriva Therapeutics plc Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q2, 2022 Results on Aug 03, 2022

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

The Nasdaq Stock Market LLC Approves Nabriva Therapeutics' Transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2021)

Nabriva Therapeutics plc to Report Q1, 2022 Results on May 05, 2022

No longer forecast to breakeven

Nabriva Therapeutics plc Announces First Patient Enrolled in Phase 1 Trial of Xenleta® (Lefamulin) in Adult Patients with Cystic Fibrosis

No longer forecast to breakeven

Forecast to breakeven in 2024

CEO & Director recently bought €51k worth of stock

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)

Independent Director George Talbot has left the company

Less than half of directors are independent

No longer forecast to breakeven

Sinovant Sciences and Nabriva Therapeutics plc Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)

Nabriva Therapeutics plc has completed a Follow-on Equity Offering in the amount of $33.7 million.

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)

Chief Financial Officer has left the company

Nabriva Therapeutics Appoints Steven Gelone to Its Board of Directors

Revenue beats expectations

Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)

Nabriva Therapeutics plc to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €1.63

Nabriva Therapeutics plc Announces A Hearing on May 14, 2021

Nabriva Therapeutics plc Announces the Publication of A Study Documenting the High Rates of Macrolide-Resistant Streptococcus Pneumoniae Throughout the United States

Nabriva Therapeutics Announces Retirement of Gary Sender as Chief Financial Officer, Effective as of March 12, 2021

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

New 90-day low: €3.05

New 90-day low: €3.18

New 90-day low: €0.32

Revenue beats expectations

Third quarter 2020 earnings released: US$0.09 loss per share

Nabriva Therapeutics plc to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €0.43

Nabriva Therapeutics plc Announces XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

New 90-day low: €0.44

New 90-day low - €0.49

New 90-day low - €0.53

Earnings released

Nabriva Therapeutics plc to Report Q2, 2020 Results on Aug 06, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad